NEW YORK (GenomeWeb) – BG Medicine said today that its common stock will be delisted from Nasdaq effective at the opening of the Dec. 4, 2015 trading session.

The company was unable to maintain compliance with listing requirements for the exchange.

BG was notified on March 10, 2015 that its stock no longer qualified for listing on the exchange because it did not have a minimum bid price of at least $1 per share, and the company’s stockholder’s equity was not at least $2.5 million.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.